Introduction {#H1-1-ZLD200021}
============

Small node-negative, hormone receptor (HR)--positive, ERBB2 (previously HER2/neu)--positive tumors represent a heterogenous category of breast cancer, with recurrence rates ranging from less than 5% up to 25% at 5 years, with or without adjuvant treatments.^[@zld200021r1],[@zld200021r2]^ The current National Comprehensive Cancer Network guideline^[@zld200021r3]^ acknowledges the lack of representation of T1a and T1b tumors in prior randomized trials and, thus, recommends the consideration of chemotherapy for tumors 1 cm or smaller at the discretion of clinicians. In the absence of randomized trial data on the role of chemotherapy for small tumors, the cutoff size at which chemotherapy should be omitted remains unclear. Using a national-level hospital registry, we conducted an observational cohort study to address this knowledge gap.

Methods {#H1-2-ZLD200021}
=======

The US National Cancer Database was queried for female patients with HR-positive, ERBB2-positive, pT1a-bN0 breast cancer diagnosed between 2010 and 2015 who received hormone therapy with or without chemotherapy. Ethical approval was waived by the Roswell Park Comprehensive Cancer Center institutional review board, because the National Cancer Database is a deidentified data set. This study follows the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](http://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline.

The Kaplan-Meier method and Cox multivariable analysis were performed to analyze overall survival. Propensity score matching was based on the nearest neighbor method in a 1:1 ratio without a replacement. The standardized difference between variables was less than 0.1, indicating appropriate matching.^[@zld200021r4]^ All *P* values were 2-sided, with *P* \< .05 considered statistically significant. R statistical software version 3.6.1 (R Project for Statistical Computing) was used for all analyses. Data analysis was performed from November 2019 to January 2020. Additional details are shown in the eAppendix in the [Supplement](#note-ZLD200021-1-s){ref-type="supplementary-material"}.

Results {#H1-3-ZLD200021}
=======

A total of 10 065 patients (median \[interquartile range\] age, 59 \[51-67\] years) were identified, including 5346 patients who received chemotherapy and 4719 patients who did not (ERBB2-directed therapy was coded distinctly from chemotherapy during 2013 to 2015, and only 15% of such patients underwent either chemotherapy or ERBB2-directed therapy alone; data not shown) ([Table](#zld200021t1){ref-type="table"}). The median (interquartile range) follow-up was 41.8 (24.3-62.6) months. On multivariable analysis, multiagent chemotherapy was associated with improved overall survival (hazards ratio \[HR\], 0.69; 95% CI, 0.52-0.90; *P* = .006), and tumor size as a continuous variable was associated with worse mortality (for every 1-mm increase, HR, 1.07; 95% CI, 1.03-1.12; *P* = .002). There was a statistically significant interaction between multiagent chemotherapy and tumor size (*P*for interaction = .02). Cox multivariable analysis was repeated with each tumor size cutoff ranging from 2 mm to 9 mm, and an 8-mm cutoff was statistically significant (*P* for interaction = .01), with a large effect size and narrow 95% CI on subgroup analysis. Multiagent chemotherapy was not associated with improved overall survival for tumors smaller than 8 mm (HR, 1.00; 95% CI, 0.70-1.43; *P* = .99), compared with tumors 8 mm to 10 mm, which favors the use of chemotherapy (HR, 0.53; 95% CI, 0.36-0.78; *P* = .001). Similar findings were observed in 1641 and 648 matched pairs, respectively (tumors \<8 mm, HR, 0.88; 95% CI, 0.58-1.34; *P* = .55; tumors 8-10 mm, HR, 0.48; 95% CI, 0.27-0.85; *P* = .01) ([Figure](#zld200021f1){ref-type="fig"}).

###### Baseline Characteristics of Matched Cohorts

  Characteristic                                                           Participants, No. (%) (N = 2289)                                                                   
  ------------------------------------------------------------------------ ---------------------------------- ----------------- ----------- ---------------- ---------------- -------
  Facility volume                                                                                                                                                             
  Low                                                                      127 (8)                            126 (8)           .99         48 (7)           57 (9)           .28
  Intermediate                                                             367 (22)                           364 (22)          168 (26)    146 (23)                          
  High                                                                     1147 (70)                          1151 (70)         432 (67)    445 (69)                          
  Total                                                                    1641 (100)                         1641 (100)        648 (100)   648 (100)                         
  Facility type                                                                                                                                                               
  Nonacademic                                                              1035 (63)                          1021 (62)         .08         462 (71)         459 (71)         .68
  Academic                                                                 534 (33)                           519 (32)          178 (27)    184 (28)                          
  Not available                                                            72 (4)                             101 (6)           8 (1)       5 (1)                             
  Total                                                                    1641 (100)                         1641 (100)        648 (100)   648 (100)                         
  Age, y                                                                                                                                                                      
  \<50                                                                     477 (29)                           488 (30)          .88         86 (13)          84 (13)          .97
  50-74                                                                    1139 (69)                          1126 (69)         529 (82)    532 (82)                          
  ≥75                                                                      25 (2)                             27 (2)            33 (5)      32 (5)                            
  Total                                                                    1641 (100)                         1641 (100)        648 (100)   648 (100)                         
  Charlson-Deyo Comorbidity Index score                                                                                                                                       
  0                                                                        1420 (87)                          1432 (87)         .63         566 (87)         566 (87)         .68
  1                                                                        170 (10)                           167 (10)          68 (10)     72 (11)                           
  2                                                                        51 (3)                             42 (3)            14 (2)      10 (2)                            
  Total                                                                    1641 (100)                         1641 (100)        648 (100)   648 (100)                         
  Annual income                                                                                                                                                               
  Above median                                                             1124 (68)                          1147 (70)         .71         441 (68)         433 (67)         .68
  Below median                                                             512 (31)                           490 (30)          207 (32)    214 (33)                          
  Not available                                                            5 (0)                              4 (0)             0 (0)       1 (0)                             
  Total                                                                    1641 (100)                         1641 (100)        648 (100)   648 (100)                         
  Tumor histologic profile                                                                                                                                                    
  Ductal or lobular                                                        1641 (100)                         1641 (100)        NA          647 (100)        648 (100)        \>.99
  Others                                                                   0 (0)                              0 (0)             1 (0)       0 (0)                             
  Total                                                                    1641 (100)                         1641 (100)        648 (100)   648 (100)                         
  Tumor grade                                                                                                                                                                 
  Differentiated                                                                                                                .62                                           .50
  Well                                                                     144 (9)                            120 (7)           92 (14)     81 (13)                           
  Moderately                                                               823 (50)                           847 (52)          372 (57)    398 (61)                          
  Poorly                                                                   566 (34)                           567 (35)          150 (23)    135 (21)                          
  Others                                                                   5 (0)                              4 (0)             0 (0)       0 (0)                             
  Not available                                                            103 (6)                            103 (6)           34 (5)      34 (5)                            
  Total                                                                    1641 (100)                         1641 (100)        648 (100)   648 (100)                         
  Race                                                                                                                                                                        
  White                                                                    1358 (83)                          1370 (83)         .82         569 (88)         571 (88)         .97
  Black                                                                    163 (10)                           165 (10)          54 (8)      55 (8)                            
  Others                                                                   105 (6)                            93 (6)            21 (3)      19 (3)                            
  Not available                                                            15 (1)                             13 (1)            4 (1)       3 (0)                             
  Total                                                                    1641 (100)                         1641 (100)        648 (100)   648 (100)                         
  Year                                                                                                                                                                        
  2010-2012                                                                874 (53)                           868 (53)          .86         306 (47)         322 (50)         .40
  2013-2015                                                                767 (47)                           773 (47)          342 (53)    326 (50)                          
  Total                                                                    1641 (100)                         1641 (100)        648 (100)   648 (100)                         
  Lymph nodes examined, No.                                                                                                                                                   
  0-2                                                                      844 (51)                           834 (51)          .77         368 (57)         385 (59)         .23
  \>2                                                                      788 (48)                           795 (48)          279 (43)    259 (40)                          
  Not available                                                            9 (1)                              12 (1)            1 (0)       4 (1)                             
  Total                                                                    1641 (100)                         1641 (100)        648 (100)   648 (100)                         
  Hormone receptor status                                                                                                                                                     
  Estrogen receptor positive and progesterone receptor positive            1158 (71)                          1161 (71)         .94         501 (77)         499 (77)         .95
  Estrogen receptor positive or progesterone receptor positive             483 (29)                           480 (29)          147 (23)    149 (23)                          
  Total                                                                    1641 (100)                         1641 (100)        648 (100)   648 (100)                         
  Surgery                                                                                                                                                                     
  Lumpectomy                                                               956 (58)                           965 (59)          .78         445 (69)         446 (69)         \>.99
  Mastectomy                                                               685 (42)                           676 (41)          202 (31)    202 (31)                          
  Others                                                                   0 (0)                              0 (0)             1 (0)       0 (0)                             
  Total                                                                    1641 (100)                         1641 (100)        648 (100)   648 (100)                         
  Margin                                                                                                                                                                      
  Negative                                                                 1582 (96)                          1574 (96)         .76         632 (98)         638 (98)         .34
  Positive                                                                 55 (3)                             62 (4)            12 (2)      9 (1)                             
  Not available                                                            4 (0)                              5 (0)             4 (1)       1 (0)                             
  Total                                                                    1641 (100)                         1641 (100)        648 (100)   648 (100)                         
  Radiation therapy                                                                                                                                                           
  None                                                                     667 (41)                           655 (40)          .67         216 (33)         215 (33)         .80
  External beam                                                            907 (55)                           926 (56)          395 (61)    402 (62)                          
  Others                                                                   67 (4)                             59 (4)            36 (6)      31 (5)                            
  Not available                                                            0 (0)                              1 (0)             1 (0)       0 (0)                             
  Total                                                                    1641 (100)                         1641 (100)        648 (100)   648 (100)                         
  Radiation dose, median, (interquartile range), Gy                        60 (52.4-60.8)                     6.4 (53.5-61.0)   .13         60 (52.6-60.8)   60 (54.0-60.8)   .62
  Readmission within 30 d                                                                                                                                                     
  None                                                                     1564 (95)                          1541 (94)         .24         623 (96)         619 (96)         .74
  Unplanned                                                                13 (1)                             21 (1)            3 (0)       5 (1)                             
  Planned                                                                  38 (2)                             52 (3)            11 (2)      15 (2)                            
  Others                                                                   0 (0)                              1 (0)             1 (0)       0 (0)                             
  Not available                                                            26 (2)                             26 (2)            10 (2)      9 (1)                             
  Total                                                                    1641 (100)                         1641 (100)        648 (100)   648 (100)                         
  Postoperative inpatient stay duration, median (interquartile range), d   0 (0-2.0)                          0 (0-2.0)         .38         0 (0-1.0)        0 (0-1.0)        .50

Abbreviation: NA, not applicable.
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Discussion {#H1-4-ZLD200021}
==========

To our knowledge, this is the first report to suggest that there is an association between improved survival and adjuvant chemoendocrine therapy specifically for HR-positive, ERBB2-positive tumors 8 mm to 10 mm compared with those smaller than 8 mm. It is evident that tumors 10 mm and smaller represent a heterogeneous group whose treatment should be tailored to improve the risk-to-benefit ratio of systemic therapy. We acknowledge the inherent challenges of diagnostic concordance in the context of millimeter-based decisions, which underscores the importance of expert pathology review. Our study is limited by the lack of specific systemic therapy regimens. Therapy directed at ERBB2 was coded distinctly from chemotherapy during 2013 to 2015, and only 15% of such patients underwent either chemotherapy or ERBB2-directed therapy alone (data not shown). Subgroup analysis using this cohort would be difficult because of the small sample sizes, as neither systemic therapy alone is a definitive recommendation by National Comprehensive Cancer Network in this setting.^[@zld200021r3]^ Postoperative readmissions and duration of postoperative inpatient admission as proxy measures for postoperative performance status were well balanced after matching.^[@zld200021r5]^ Nevertheless, while we await results of prospective trials, including the ATEMPT trial (ClinicalTrials.gov identifier, [NCT01853748](https://clinicaltrials.gov/ct2/show/NCT01853748)), our data can help clinicians in decision-making on adjuvant systemic therapy for patients with small HR-positive, ERBB2-positive breast cancers.
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